Validation and improvements in cardiovascular risk estimation
- PMID: 40350162
- DOI: 10.1093/eurjpc/zwaf183
Validation and improvements in cardiovascular risk estimation
Conflict of interest statement
Conflict of interest: I.B. does not have any conflicts of interest to disclose. V.A. reported honoraria and institutional funding from Amarin, Amgen, AstraZeneca, Boehringer Ingelheim, Organon, Novo Nordisk, and Vifor.
LinkOut - more resources
Full Text Sources